BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:RNDO-564 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of RNDO-564\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07218003-2710@assetmemo.bio
DTSTAMP:20261121T005712Z
DTSTART;VALUE=DATE:20290228
DTEND;VALUE=DATE:20290301
SUMMARY:RNDO-564: Phase 1 readout est. (NCT07218003)
DESCRIPTION:RNDO-564\, phase 1\, Non-Small Cell Lung Cancer.\nStudy: A Phas
 e 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bl
 adder Cancer and Other Solid Tumors Associated With Nectin-4\nEstimated pr
 imary completion: 28 February 2029. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/rndo-564#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07218003
URL:https://assetmemo.bio/drug/rndo-564#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
